Drawing for DIRECTMX

USPTO serial 88614061

DIRECTMX

Reviewed by CopyMark Law Group

Reg. 6208690Status 700Renewal
Filing date
Status date
Registration date
Dec 1, 2020
Examiner
LE, MARGARET
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DIRECTMX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Timothy P. Naill

Timothy P. Naill REINHART BOERNER VAN DEUREN P.C.2215 PERRYGREEN WAYROCKFORD, IL 61107UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Biological preparations for use in industry; Biological preparations for use in science; Carriers for biologically active compounds; Biological substances, materials, preparations and elements for scientific and industrial use in vivo and in vitro; Chemical substances, chemical materials and chemical preparations, and natural elements for scientific and industrial use in vivo and in vitro; biological materials for use in industry and science; Chemical substances, materials, preparations and elements for cosmetic preparations; Biological substances, materials, preparations and elements for cosmetic preparations; Lipid nanoparticles for use in industry and science; Lipid nanoparticles comprising protein for use in industry and science; Saposin-lipid nanoparticles for use in industry and scienceACTIVE—
005Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases; Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in non-human animals; Biological reagents for medical use; Biological reagents for veterinary use; Carriers for pharmaceutical, medical, veterinary or diagnostic compounds; Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in humans and non-human animals and for use in a diagnostic method; Medicinal preparations and substances for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in humans and non-human animals; Veterinary vaccines; Human vaccine preparations; Lipid nanoparticles for medicinal, diagnostic or pharmaceutical purposes; Lipid nanoparticles comprising protein for medical, diagnostic or pharmaceutical purposes; Saposin-lipid nanoparticles for medical, diagnostic or pharmaceutical purposesACTIVE—
040Treatment of cells and/or viruses and/or biological membranes to obtain carriers for biologically active, pharmaceutical or diagnostic compounds; Conversion of cells and/or viruses and/or biological membranes into biochemical preparations; Custom manufacturing of lipid nanoparticles in particular of lipid nanoparticles comprising protein or Saposin-lipid nanoparticles; Processing of cells and/or viruses and/or biological membranes for third partiesACTIVE—
042Biological laboratory services; Biochemistry consultancy; Consulting services in the field of lipid nanoparticles in particular in the field of lipid nanoparticles comprising protein or Saposin-lipid nanoparticlesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 1, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Dec 1, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 15, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 15, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 26, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 9, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 9, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Aug 9, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 9, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 9, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 24, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jun 24, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Jun 24, 2020CNSLSUSPENSION LETTER WRITTEN—
Jun 15, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 15, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 15, 2020ALIEASSIGNED TO LIE—
Jun 4, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 19, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 19, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 19, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 13, 2019DOCKASSIGNED TO EXAMINER—
Sep 20, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 16, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance